+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Interstitial Lung Disease Market - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

  • ID: 5509670
  • Report
  • November 2021
  • Region: Global
  • 260 Pages
  • Coherent Market Insights Pvt Ltd.

FEATURED COMPANIES

  • Cipla
  • Company Overview
  • F. Hoffmann-La Roche Ltd
  • Financial Performance
  • Glenmark Pharma
  • Liminal Biosciences
Interstitial lung disease (ILD) is a term used for group of diseases that cause scarring (fibrosis) of the lungs. This scarring causes stiffness in the lungs, which makes difficult to breathe and supply oxygen to the bloodstream. Interstitial lung disease can be caused due to long-term exposure to hazardous materials such as asbestos. Some types of autoimmune diseases, such as rheumatoid arthritis, also can cause interstitial lung disease. The symptoms of interstitial lung disease include:


  • Shortness of breath at rest
  • Dry cough
The diseases which are grouped under interstitial lung disease are interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis. Interstitial lung disease (ILD) can be treated with medications such as corticosteroids, anti-fibrotic medication, Pirfenidone, and nintedanib.

Market Dynamics


Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period. For instance, in October 2014, the U.S. Food and Drug Administration (FDA) approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease that makes breathing difficult and causes irreversible lung damage.

Increasing number of drug launches is expected to drive the growth of global interstitial lung disease market. For instance, in October 2020, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of NINDANIB (Nintedanib 100 and 150 mg capsules) for the treatment of pulmonary fibrosis in India.

Key features of the study:

  • This report provides an in-depth analysis of global interstitial lung disease market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global interstitial lung disease market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
  • Key companies covered as a part of this study include MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd., and Cipla
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global interstitial lung disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the interstitial lung disease market.

Detailed Segmentation:


Global Interstitial Lung Disease Market, By Disease Type:

  • Interstitial Pneumonia
  • Idiopathic Pulmonary Fibrosis
  • Nonspecific Interstitial Pneumonitis
  • Hypersensitivity Pneumonitis
  • Cryptogenic Organizing Pneumonia (COP)
  • Sarcoidosis
  • Acute Interstitial Pneumonitis

Global Interstitial Lung Disease Market, By Drug Type:

  • Corticosteroids
  • Anti-fibrotic Medication
  • Pirfenidone
  • Nintedanib

Global Interstitial Lung Disease Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Interstitial Lung Disease Market, By Region:

  • North America
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • MSD (Merck) *
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Liminal Biosciences
  • Glenmark Pharma
  • J.B. Chemicals & Pharmaceuticals
  • Boehringer Ingelhim International GmbH
  • F. Hoffmann-La Roche Ltd
  • Cipla
Frequently Asked Questions about the Interstitial Lung Disease Market

What is the estimated value of the Interstitial Lung Disease Market?

The Interstitial Lung Disease Market was estimated to be valued at US$1578.9 Million in 2021.

What is the growth rate of the Interstitial Lung Disease Market?

The growth rate of the Interstitial Lung Disease Market is 6.5%, with an estimated value of US$2453.5 Million by 2028.

What is the forecasted size of the Interstitial Lung Disease Market?

The Interstitial Lung Disease Market is estimated to be worth US$2453.5 Million by 2028.

Who are the key companies in the Interstitial Lung Disease Market?

Key companies in the Interstitial Lung Disease Market include MSD (Merck), Company Overview, Product Portfolio, Financial Performance, Recent Highlights, Strategies, Liminal Biosciences, Glenmark Pharma and Boehringer Ingelhim International GmbH.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Cipla
  • Company Overview
  • F. Hoffmann-La Roche Ltd
  • Financial Performance
  • Glenmark Pharma
  • Liminal Biosciences

1. Research Objectives and Assumptions
  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview
  • Report Description
  • Market Definition and Scope
  • Executive Summary
  • Market Snippet, By Disease Type
  • Market Snippet, By Drug Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis
  • Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
  • Impact Analysis
  • Key Development
  • Market Trends
  • Technology Landscape
  • New Device/Product Launches
  • PEST Analysis
  • Porter’s Five Forces Analysis

4. COVID – 19 Impact Analysis
  • Impact on Demand
  • Impact on Healthcare

5. Global Interstitial Lung Disease, By Disease Type, 2017-2028 (US$ Million)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
  • Interstitial Pneumonia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Idiopathic Pulmonary Fibrosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nonspecific Interstitial Pneumonitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Hypersensitivity Pneumonitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Cryptogenic Organizing Pneumonia (COP)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Sarcoidosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Acute Interstitial Pneumonitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Interstitial Lung Disease, By Drug Type, 2017 - 2028 (US$ Million)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
  • Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Anti-fibrotic Medication
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Pirfenidone
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Nintedanib
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Interstitial Lung Disease, By Distribution Channel, 2017 - 2028 (US$ Million)
  • Introduction
  • Market Share Analysis, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, 2018 - 2028
  • Segment Trends
  • Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Interstitial Lung Disease, By Region, 2017 - 2028 (US$ Million)
  • Introduction
  • Market Share Analysis, By Region, 2021 and 2028 (%)
  • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
  • Regional Trends
  • North America
  • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • U.S.
  • Canada
  • Latin America
  • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

9. Competitive Landscape
  • Company Profiles
  • MSD (Merck)
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Liminal Biosciences
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Glenmark Pharma
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • J.B. Chemicals & Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Boehringer Ingelhim International GmbH
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Cipla
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
  • Analyst Views

10. Section
  • References
  • Research Methodology
  • About us and Sales Contact
Note: Product cover images may vary from those shown
  • MSD (Merck)
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Liminal Biosciences
  • Glenmark Pharma
  • J.B. Chemicals & Pharmaceuticals
  • Boehringer Ingelhim International GmbH
  • F. Hoffmann-La Roche Ltd
  • Cipla
Note: Product cover images may vary from those shown